Human IGFBP‑6 Antibody

Name: Human IGFBP‑6 Antibody
Brand: R&D Systems
SKU: AF876
Rating: 2 (2 reviews)

Catalog # AF876 | R&D Systems, Inc. a Bio-Techne Brand

(2)

Citations (1)

Product Datasheet / COA / SDS

100% Guarantee

Product Summary
Scientific Data
Applications
Preparation & Storage
Background
Product Documents
Specific Notices

Key Product Details

Species Reactivity

Human

Applications

Neutralization, Western Blot

Label

Unconjugated

Antibody Source

Polyclonal Goat IgG

Product Summary for Human IGFBP‑6 Antibody

Immunogen

Mouse myeloma cell line NS0-derived recombinant human IGFBP-6
Ala25-Gly240
Accession # NP_002169

Specificity

Detects human IGFBP‑6 in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 30% cross‑reactivity with recombinant mouse IGFBP-6 is observed, 5% cross‑reactivity with recombinant human (rh) IGFBP-2 is observed and less than 1% cross‑reactivity with rhIGFBP-1, rhIGFBP-3, rhIGFBP-4, and rhIGFBP-5 is observed.

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Scientific Data Images for Human IGFBP‑6 Antibody

IGFBP‑6 Inhibition of IGF‑II-dependent Cell Proliferation and Neutralization by Human IGFBP‑6 Antibody.

Recombinant Human IGFBP-6 (Catalog # 876-B6) inhibits Recombinant Human IGF-II (Catalog # 292-G2) induced proliferation in the MCF-7 human breast cancer cell line in a dose-dependent manner (orange line). Inhibition of Recombinant Human IGF-II (14 ng/mL) activity elicited by Recombinant Human IGFBP-6 (0.8 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IGFBP-6 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF876). The ND₅₀ is typically 8-24 µg/mL.

Applications for Human IGFBP‑6 Antibody

Application

Recommended Usage

Western Blot

0.1 µg/mL
Sample: Recombinant Human IGFBP‑6 (Catalog # 876-B6)

Neutralization

Measured by its ability to neutralize IGFBP‑6 inhibition of IGF‑II-dependent proliferation in the MCF‑7 human breast cancer cell line. Karey, K. P. et al. (1988) Cancer Research 48:4083. The Neutralization Dose (ND₅₀) is typically 8‑24 µg/mL in the presence of 0.8 µg/mL Recombinant Human IGFBP‑6 and 14 ng/mL Recombinant Human IGF‑II.

Please Note: Optimal dilutions of this antibody should be experimentally determined.

Reviewed Applications

Read 2 reviews rated 2 using AF876 in the following applications:

Immunocytochemistry/Immunofluorescence (1 Review)
Western Blot (1 Review)

Published Applications

Read 1 publication using AF876 in the following applications:

Western Blot (1 Publication)

Formulation, Preparation and Storage

Purification

Antigen Affinity-purified

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS.

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IGFBP-6

The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and at least four additional low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-transitional modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Human IGFBP-6 cDNA encodes a 240 amino acid (aa) residue precursor protein with a putative 24 aa residue signal peptide that is processed to generate the 216 aa residue mature protein that is O-glycosylated. IGFBP-6 is expressed in ovarian cells, prostatic cells, and fibroblasts. IGFBP‑6 is found predominantly in CSF and serum. IGFBP-6 binds preferentially to IGF-II, exhibiting a 2-fold higher affinity for IGF-II than for IGF-I.

References

Jones, J.I. and D.R. Clemmons (1995) Endocrine Rev. 16:3.
Kelley, K.M. et al. (1996) Int. J. Biochem. Cell Biol. 28:619.

Long Name

Insulin-like Growth Factor Binding Protein 6

Alternate Names

IGFBP6

Entrez Gene IDs

3489 (Human); 16012 (Mouse)

Gene Symbol

IGFBP6

UniProt

NP_002169

Product Documents for Human IGFBP‑6 Antibody

Product Datasheets

Download Product Datasheets

COA

SDS

Download SDS

Product Specific Notices for Human IGFBP‑6 Antibody

For research use only

Citations
Reviews

Citations for Human IGFBP‑6 Antibody (1)

Showing 1 - 1 of 1 publication Showing All

Filter By:

Search Title:

Citations are publications that use Bio-Techne products. Selected citations for Human IGFBP‑6 Antibody include:

Species: Human
Sample Types: Cell Lysates
Applications: Western Blot

McCaig C et al. (2006-03-06), The role of matrix metalloproteinase-7 in redefining the gastric microenvironment in response to Helicobacter pylori. Gastroenterology, 2006-0130(6):1754-63.
PMID: 16697739

There are no citations that match your criteria.

Showing 1 - 1 of 1 publication Showing All

Customer Reviews for Human IGFBP‑6 Antibody (2)

2 out of 5

2 customer ratings

5 stars

4 stars

3 stars

50%

2 stars

1 star

50%

Customer Images

Showing 1 - 2 of 2 reviews Showing All